Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Exelixis stock | $18.01

Learn how to easily invest in Exelixis stock.

Exelixis Inc (EXEL) is a leading biotechnology business based in the US. It opened the day at $18.03 after a previous close of $17.83. During the day the price has varied from a low of $17.87 to a high of $18.32. The latest price was $18.01 (25 minute delay). Exelixis is listed on the NASDAQ and employs 773 staff. All prices are listed in US Dollars.

How to buy shares in Exelixis

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EXEL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Exelixis stock price (NASDAQ: EXEL)

Use our graph to track the performance of EXEL stocks over time.

Exelixis shares at a glance

Information last updated 2021-07-09.
Previous close$17.83
Change $0.18
Change % 1.0095%
Volume 1,306,706
Information last updated 2021-10-23.
52-week range$16.19 - $25.77
50-day moving average $20.80
200-day moving average $20.95
Wall St. target price$31.46
PE ratio 73.0375
Dividend yield N/A (0%)
Earnings per share (TTM) $0.29

Buy Exelixis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Exelixis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Exelixis price performance over time

Historical closes compared with the close of $18.01 from 2021-10-25

1 week (2021-10-19) -16.23%
1 month (2021-09-27) -13.00%
3 months (2021-07-27) 8.17%
6 months (2021-04-27) -26.88%
1 year (2020-10-26) -17.76%
2 years (2019-10-25) 4.41%
3 years (2018-10-26) 25.24%
5 years (2016-10-26) 61.09%

Is Exelixis under- or over-valued?

Valuing Exelixis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Exelixis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Exelixis's P/E ratio

Exelixis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 73x. In other words, Exelixis shares trade at around 73x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Exelixis's PEG ratio

Exelixis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4174. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Exelixis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Exelixis's EBITDA

Exelixis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $114.5 million.

The EBITDA is a measure of a Exelixis's overall financial performance and is widely used to measure a its profitability.

Exelixis financials

Revenue TTM $1.2 billion
Operating margin TTM 8.89%
Gross profit TTM $954 million
Return on assets TTM 2.91%
Return on equity TTM 4.85%
Profit margin 8.13%
Book value $6.49
Market capitalisation $6.7 billion

TTM: trailing 12 months

Shorting Exelixis shares

There are currently 10.2 million Exelixis shares held short by investors – that's known as Exelixis's "short interest". This figure is 2.1% up from 10.0 million last month.

There are a few different ways that this level of interest in shorting Exelixis shares can be evaluated.

Exelixis's "short interest ratio" (SIR)

Exelixis's "short interest ratio" (SIR) is the quantity of Exelixis shares currently shorted divided by the average quantity of Exelixis shares traded daily (recently around 1.8 million). Exelixis's SIR currently stands at 5.56. In other words for every 100,000 Exelixis shares traded daily on the market, roughly 5560 shares are currently held short.

However Exelixis's short interest can also be evaluated against the total number of Exelixis shares, or, against the total number of tradable Exelixis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Exelixis's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Exelixis shares in existence, roughly 30 shares are currently held short) or 0.0366% of the tradable shares (for every 100,000 tradable Exelixis shares, roughly 37 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Exelixis.

Find out more about how you can short Exelixis stock.

Exelixis share dividends

We're not expecting Exelixis to pay a dividend over the next 12 months.

Exelixis share price volatility

Over the last 12 months, Exelixis's shares have ranged in value from as little as $16.19 up to $25.77. A popular way to gauge a stock's volatility is its "beta".

EXEL.US volatility(beta: 1)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exelixis's is 1.0011. This would suggest that Exelixis's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Exelixis overview

Exelixis, Inc. , an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer.

Frequently asked questions

What percentage of Exelixis is owned by insiders or institutions?
Currently 1.986% of Exelixis shares are held by insiders and 86.487% by institutions.
How many people work for Exelixis?
Latest data suggests 773 work at Exelixis.
When does the fiscal year end for Exelixis?
Exelixis's fiscal year ends in January.
Where is Exelixis based?
Exelixis's address is: 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502
What is Exelixis's ISIN number?
Exelixis's international securities identification number is: US30161Q1040
What is Exelixis's CUSIP number?
Exelixis's Committee on Uniform Securities Identification Procedures number is: 30161Q104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site